Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $40 from $38 and keeps an Outperform rating on the shares. The firm notes ...

It has been about a month since the last earnings report for Exelixis (EXEL). Shares have added about 13.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The ...

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other best immunology stocks to buy now. The Growing Market for Immune System Treatments ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Exelixis is experiencing significant insider selling activity while its stock trades near its 52-week high of €37.64. Three ...

Research analysts at Zacks Research dropped their Q1 2025 EPS estimates for Exelixis in a research report issued on Monday, March 3rd. Zacks Research analyst E. Bagri now forecasts that the ...

Net income for Q4 2024 increased by 63.7% to $139.9 million from $85.5 million in Q4 2023. Exelixis is targeting 2025 revenue of $2.15 billion to $2.25 billion. Exelixis reported increased revenue ...

Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by equities researchers at Wells Fargo & Company from an “overweight” ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...